The World Without Disease Summit
Delivering future health through disease interception
Join us on 21st June 2023
Welcome
pharmaphorum is proud to announce its inaugural “The World Without Disease Summit”: a high quality, event bringing together key global leaders and innovators to explore the potential of disease interception in future health, which has been conceived in partnership with an established industry leader in this space, Ben Wiegand, Founding Partner at CWWDA (The Connected World Without Disease Accelerator) and former senior executive at United Health and Janssen. The World Without Disease Summit recognises that health systems globally have reached a critical inflexion point, where aging populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic disease. Instead, a new paradigm is needed where equal emphasis is placed on earlier disease prediction, prevention, and interception, which can deliver vastly improved outcomes for patients in a much more sustainable manner. Delivering on this vision requires strong collaboration between multiple stakeholders within the industry and health systems, most notably those addressing the clinical, regulatory and investment challenges that must be addressed to realise this opportunity. This is the vision of a World Without Disease, which necessitates bringing together the key stakeholders, plus the latest medical and digital technologies. Join us on the 21st June 2023 in London, where the smartest minds in these fields will convene to understand how we can bring this vision to life.
Schedule
Event
(Wed 21st June)
Guy Whittle Auditorium
| 8:30 – 9:00
Registration and coffee
| 9:00 – 10:50
A vision for a World Without Disease
9:00 – 9:10
Introduction and agenda (Paul Tunnah, Founder, pharmaphorum)
9:10 – 9:30
Opening keynote: A World Without Disease (Ben Wiegand, Founding Partner, CWWDA and Laura McCulloch, Medical Advisor, CWWDA, and General Practitioner)
9:30 – 10:00
Is Obesity a choice? (Prof. Giles Yeo, University of Cambridge)
10:00 – 10:30
Panel: Why our voices matter – patient centric approaches for a World Without Disease (Stephen Head, Senior Director, Patient Partnerships, Astellas, and patient representatives)
| 10:30 – 10:50
Morning coffee
| 10:50 – 12:30
Recent breakthroughs
10:50 – 11:20
Fireside Chat: Transformational Diagnostics (Sir Harpal Kumar, President, GRAIL Europe)
11:20 – 11:50
Fireside Chat: Intercepting disease - the type 1 diabetes story (Francisco Leon, Chief Scientific Officer & Co-Founder, Provention Bio, a Sanofi Company)
11:50 – 12:10
Preventing Childhood Food Allergies (Daniel Zakowski , CEO, Ready Set Food)
12:10 – 12:40
Panel: expectations for future breakthroughs
| 12:40 – 13:40
Lunch
| 13:40 – 15:00
New initiatives pushing boundaries
13:40 – 14:00
The role of the microbiome in early childhood (Mike Johnson, CEO, Infinant Health)
14:00 – 14:20
Prospects for Prevention of Pediatric Allergic Disease (Richard Insel, M.D., Head of Pediatric Health and Wellness, Kenvue (formerly the Consumer sector of Johnson & Johnson)
14:20 – 14:40
How digital health can help enable a World Without Disease (Kristin Milburn, CMO & MD Publications, Events & Digital Health Ecosystem, Healthware Group)
14:40 – 15:00
Preemptive medicine (Hutan Ashrafian, Chief Scientific Officer - Preemptive Medicine and Health Security, Flagship Pioneering)
| 15:00-15:20
Afternoon coffee
| 15:20-18:00
Scaling a World Without Disease
15:20 – 15:50
Fireside chat: the payer perspective (Ken Ehlert, Former Chief Scientific Officer, UnitedHealth Group)
15:50 – 16:20
Pharma’s role and experience in scaling a World Without Disease (Stefan Woxström, SVP Europe and Canada, AstraZeneca and Stefan Vlachos, Head of Health Works, AstraZeneca)
16:20 – 16:40
The role for Real-World Evidence (Christine Lemke, CEO, Evidation)
16:40 – 17:00
Bringing the Vision to Life: Harnessing the Principles of Disruptive Innovation to Catalyze Systemic Change (Josh Suskewicz, Partner, Innosight)
17:00 – 17:40
Closing panel: bringing the vision to life
17:40 – 18:00
Closing comments (Ben Wiegand, Founding Partner, CWWDA)
| 18:00-19:00
Drinks Reception & Networking
All timings are approximate.
Dress code: business casual
Dress code: business casual
Please contact our event manager, Matthew Brookes for more information:
[email protected]
[email protected]
Interested in speaking at the event?
Please contact our event manager, Matthew Brookes
[email protected]
Please contact our event manager, Matthew Brookes
[email protected]
Ken Ehlert
Former Chief Scientific Officer, UnitedHealth Group
Ken spent the early years of his career working across the industries of agriculture, finance, and retail, before finding a home in healthcare. Since then, he has focused on using data, analytics, and a longitudinal understanding of disease to build products and businesses that improve the healthcare system. This career spans three decades and consists of numerous leadership positions and entrepreneurial endeavors, including serving as UnitedHealth Group’s Chief Scientific Officer. Ken has founded and successfully exited several companies, including All Savers – a novel insurance product for small businesses that brings the advantages of large groups, Motion – the first pay-for-healthy-behaviors insurance program that used biosensors, Level2 – the first insurance plan that combines disease-specific interventions with benefit design, and Savvysherpa – a healthcare R&D firm focused at the intersection of math, clinical science, and human connection.
Sir Harpal Kumar
President, GRAIL Europe
Sir Harpal is the President of BioPharma Business and Europe for GRAIL. Prior to GRAIL, he was Senior Vice President and Head of Innovation EMEA at Johnson & Johnson. Before joining Johnson & Johnson, Sir Harpal spent more than 15 years with Cancer Research UK (CRUK) and served as the organisation’s Chief Executive Officer from April 2007 until June 2018. Prior to this, he was Chief Operating Officer & Executive Director of Development at CRUK and served as Chief Executive of Cancer Research Technology (a subsidiary of CRUK). Before CRUK, he worked with McKinsey & Co, and was CEO of The Papworth Trust and Nexan Group.
He is a Board Member of Our Future Health and Chair of Our Future Health Trading Ltd. He chairs the Global Advisory Group for the Cambridge Cancer Research Hospital and is a member of the President's Advisory Council for the European Association of Cancer Research. He is a member of the Oversight Committee of the Covid-19 National Core Studies. In 2016, he was knighted by Her Majesty Queen Elizabeth II for services to cancer research.
He is a Board Member of Our Future Health and Chair of Our Future Health Trading Ltd. He chairs the Global Advisory Group for the Cambridge Cancer Research Hospital and is a member of the President's Advisory Council for the European Association of Cancer Research. He is a member of the Oversight Committee of the Covid-19 National Core Studies. In 2016, he was knighted by Her Majesty Queen Elizabeth II for services to cancer research.
Giles Yeo
Professor of Molecular Neuroendocrinology, University of Cambridge
Giles Yeo got his PhD in molecular genetics from the University of Cambridge in 1998, after which he joined the lab of Prof. Sir Stephen O’Rahilly, working on the genetics of severe human obesity. Giles Yeo is now a Professor of Molecular Neuroendocrinology and programme leader at the MRC Metabolic Diseases Unit in Cambridge and his research currently focuses on the influence of genes on feeding behaviour and body-weight. In addition, he is a graduate tutor and fellow of Wolfson College, and Honorary President of the British Dietetic Association. Giles is also a broadcaster and author, presenting science documentaries for the BBC, and hosts a podcast called ‘Dr Giles Yeo Chews The Fat’. His first book ‘Gene Eating’ was published in December 2018, and his second book ‘Why Calories Don’t Count’ came out in June 2021. Giles was appointed an MBE in the Queen’s 2020 birthday honours for services to ‘Research, Communication and Engagement’. He won the Society for Endocrinology Medal in 2022.
Hutan Ashrafian
Chief Scientific Officer, Preemptive Medicine and Health Security, Flagship Pioneering
Professor Hutan Ashrafian is a clinician-scientist, entrepreneur and active surgeon translating novel technologies and therapeutics in healthcare and policy. He has over 20 years of translational clinical, computational physiology, robotic surgery, health policy, digital and AI trial and product development experience including fundamental contributions in the systems biology and clinical practice of Metabolic-Bariatric Surgery, development of novel bio-incubator COVID vaccines, online teaching tools and national tracing apps. He is currently the Lead for Applied Artificial Intelligence (AI) and Big Data at the Institute of Global Health Innovation at Imperial College London and Chief Scientific Officer of Preemptive Health at the largest global venture incubator – Flagship Pioneering, which generated Moderna.
Stephen Head
Senior Director, Patient Partnerships,
Astellas
Astellas
Stephen started his working life as a paediatric nurse, first in oncology and bone marrow transplant, then latterly in HIV. After moving into the pharmaceutical industry in 2003 to work in HIV patient advocacy, Stephen joined Astellas in 2020 to help kickstart the company's patient centricity function in Europe.
Richard Insel
Head of Pediatric Health and Wellness, Kenvue
Richard Insel, M.D. is the Head of Pediatric Health and Wellness at Kenvue (formerly the Consumer sector of Johnson & Johnson). Prior to joining Kenvue, Dr. Insel was the Global Head, Healthy Baby Initiative, World Without Disease Accelerator, Janssen R&D from 2018-2022. The Healthy Baby Initiative was focused on developing interventions to decrease the risk of childhood allergic disease. Prior to joining Janssen, he was Executive Vice President of Research and Chief Scientific Officer at the Juvenile Diabetes Research Foundation (JDRF) from 2003-2016. From 1977 to 2003, Dr. Insel was affiliated with the University of Rochester Medical Center where he held several positions during his tenure including Professor of Pediatrics and Microbiology/ Immunology, founding Director of the Center for Human Genetics and Molecular Pediatric Disease, Director of the Strong Children’s Research Center, and Chief of the Division of Pediatric Immunology, Allergy, and Rheumatology.
Mike Johnson
CEO, Infinant Health
Mike Johnson is a seasoned senior executive with nearly 20 years of experience leading companies in the health and technology sectors. He is deeply passionate about Infinant Health’s mission to leverage the power of the microbiome to positively impact lives. Prior to joining Infinant Health, Johnson served as the Global Managing Director at Cargill Animal Health Technologies, where he led a team of 500 professionals responsible for developing and distributing technology on a global scale. Before leading the Animal Health business, he was instrumental in standing up Cargill’s approach to Health Technologies broadly. He was responsible for the human health supplement EpiCor and the organic and inorganic growth portfolio for health. In this capacity Mike led the most recent series for Infinant Health and participated in investments in both private and public companies. Mike’s passion for science and technology, coupled with his business acumen, has allowed him to successfully bring new products to market on a global scale. Mike also served on Infinant Health’s Board of Directors prior to being named Chief Executive Officer.
Christine Lemke
CEO, Evidation
Christine is the Co-Founder and Chief Executive Officer of Evidation. Previously, Christine was the Co-Founder and Chief Operating Officer of Sense Networks, developers of the first machine learning platform for mobile phone activity data (exited to YP.com). She has also held roles at 3iGroup (Paris) and Microsoft XBOX, and co-founded Chicago-based Channel IQ, a product analytics platform. Christine has a BA from the University of Washington and an MBA from HEC Paris.
Francisco Leon
Chief Scientific Officer & Co-Founder, Provention
Francisco Leon, MD, PhD, is the CSO and cofounder of Provention Bio, a Sanofi company. He has a breadth of experience across all areas of immunology from his clinical, academic and industry careers. He is a basic and clinical immunologist by training, with a strong interest in immune tolerance and immune disease interception and prevention. He has been a drug and vaccine developer at BMS, MedImmune/AZ and Centocor/Janssen, with 20+ years’ experience, and significant contributions to six drugs on the market. He cofounded Celimmune, as CEO and CMO, which was acquired by Amgen in 2017, before going on to cofound diagnostics company Glutenostics. Francisco has authored or co-authored more than 100 peer-reviewed articles, book chapters, and patents.
Laura McCulloch
Medical Advisor, CWWDA, and General Practitioner
Laura initially graduated with a PhD in Chemistry and worked in the US as a research scientist in the Healthcare area before retraining to become a medical doctor, qualifying in 2010 from University of Southampton, UK.
She has worked as a General Practitioner (Family Medicine Physician) in primary care in the UK and the Middle East and is a proponent of the need for an increased focus on early interception and disease prevention.
She has worked as a General Practitioner (Family Medicine Physician) in primary care in the UK and the Middle East and is a proponent of the need for an increased focus on early interception and disease prevention.
Kristin Milburn
CMO & MD Publications, Events & Digital Health Ecosystem, Healthware Group
A twenty+ year veteran of consulting and digital marketing, Kristin’s experience has had a consistent focus on healthcare, technology and the intersection of the two.
She is a strategic and innovative thinker, who has held leadership roles in strategy/planning and client engagement at various digital firms with numerous Fortune 100 pharmaceutical and technology clients.
After launching her own digital shop and rising through the ranks on the agency side, Kristin jumped to the client side and joined the newly formed unit at Novartis called Digital Medicines in 2015. In that role, she looked to make transversal connections from other industries and find diverse partners from all corners of the healthcare ecosystem and beyond to help accelerate the experimentation and adoption of new digital health solutions to improve the lives of patients.
Headspace was one such solution she felt could have significant impact across a variety of disease states, and joined the team there to integrate mindfulness/meditation into healthcare.
She is a strategic and innovative thinker, who has held leadership roles in strategy/planning and client engagement at various digital firms with numerous Fortune 100 pharmaceutical and technology clients.
After launching her own digital shop and rising through the ranks on the agency side, Kristin jumped to the client side and joined the newly formed unit at Novartis called Digital Medicines in 2015. In that role, she looked to make transversal connections from other industries and find diverse partners from all corners of the healthcare ecosystem and beyond to help accelerate the experimentation and adoption of new digital health solutions to improve the lives of patients.
Headspace was one such solution she felt could have significant impact across a variety of disease states, and joined the team there to integrate mindfulness/meditation into healthcare.
Josh Suskewicz
Partner, Innosight
Josh Suskewicz is a partner at Innosight, a growth strategy consulting firm, where he leads the life sciences and medical technologies group. His work focuses on partnering with leadership teams to transform their organizations in response to disruptive change, in particular, identifying high-potential growth opportunities, accelerating the development of promising emerging technologies, and guiding the creation of new business models. Josh is an accomplished speaker and facilitator, having led dozens of client workshops and keynoted innovation conferences around the world. He is the coauthor of the award-winning book Lead from the Future: How to Turn Visionary Thinking Into Breakthrough Growth as well as several Harvard Business Review articles.
Paul Tunnah
Founder, pharmaphorum
Dr Paul Tunnah is Chief Content Officer and Managing Director for Healthware International, a global health innovation and technology leader providing transformational advisory and technology services for commercial, medical, and R&D operations of life-sciences and digital health companies, combined with design and development of digital medicines and digital therapeutics products.
Prior to this, he founded the industry-leading publication, pharmaphorum, in 2009, which also provides broader content communications and marketing services to enable more effective customer engagement. He is a recognised author, speaker, moderator and industry advisor with a passion for helping organisations tell authentic stories that resonate, co-create solutions and unlock the power of digital and social media in connecting with stakeholders and understanding markets.
Prior to this, he founded the industry-leading publication, pharmaphorum, in 2009, which also provides broader content communications and marketing services to enable more effective customer engagement. He is a recognised author, speaker, moderator and industry advisor with a passion for helping organisations tell authentic stories that resonate, co-create solutions and unlock the power of digital and social media in connecting with stakeholders and understanding markets.
Stefan Vlachos
Head, Health Works, AstraZeneca
Stefan Vlachos is Head of Health Works at AstraZeneca. He previously held senior roles at the Karolinska University Hospital, including six years as the Head of the Centre for Innovation. He has over 25 years’ experience spanning many industries, and he currently sits on the selection committee of non-profit organization Innovationsledarna and the board of Umansense, a start-up. Stefan is one of the world’s first Certified Innovation Managers. He has held C-level and board leadership roles at start-ups and established media and technology companies. Stefan earned his MBA from INSEAD and an MSc in Engineering Physics from the Faculty of Engineering at Lund University.
Ben Wiegand
Founding Partner CWWDA
Ben is currently, Founding Partner Connected World Without Disease Accelerator (CWWDA) focusing on shifting the paradigm in healthcare from diagnosing and treating disease to identifying early risk for disease and intercepting disease processes before they progress to illness. These efforts require the integration of many stakeholders, spanning scientific, clinical, regulatory, and commercial - all aligned to a vision, focused on the individual, creating wins for the patient, provider and payer together. Currently, he is continuing to build awareness on the current set of clinical successes in this space, as well as translating these clinical successes into patient and commercial successes for people and health care systems around the world. Through these efforts, the goal is to attract significant financial and human capital into this field, allowing for the next round of innovations that are necessary... each step getting closer to a world without disease.
Stefan Woxström
SVP Europe and Canada, AstraZeneca
Stefan Woxström is Senior Vice President, Europe & Canada (EUCAN) at AstraZeneca, responsible for leading the company’s sales, marketing and commercial operations in 30 European countries and Canada.
Stefan has been with AstraZeneca since 1996, when he began his professional career. He started as a Sales Representative for AstraZeneca Sweden, before becoming National Sales Manager, National Sales Director and Marketing Director Cardiovascular, respectively. In 2008, he was appointed Regional Business Director, Specialty Care of AstraZeneca’s former ‘Central Eastern Europe Middle East and Africa’ (CEEMEA) Office in Belgium. A year later, Stefan was promoted to Country President of Ukraine & the Commonwealth of Independent States (CIS), serving in this role until 2012. This was followed by three further leadership roles as Country President for Turkey (2012–2014), the Nordic-Baltics region (2014–2017), and most recently, Japan (2018–2022). Stefan also serves as a Board Member of EFPIA (European Federation of Pharmaceutical Industry Association) in Europe.
Stefan has been with AstraZeneca since 1996, when he began his professional career. He started as a Sales Representative for AstraZeneca Sweden, before becoming National Sales Manager, National Sales Director and Marketing Director Cardiovascular, respectively. In 2008, he was appointed Regional Business Director, Specialty Care of AstraZeneca’s former ‘Central Eastern Europe Middle East and Africa’ (CEEMEA) Office in Belgium. A year later, Stefan was promoted to Country President of Ukraine & the Commonwealth of Independent States (CIS), serving in this role until 2012. This was followed by three further leadership roles as Country President for Turkey (2012–2014), the Nordic-Baltics region (2014–2017), and most recently, Japan (2018–2022). Stefan also serves as a Board Member of EFPIA (European Federation of Pharmaceutical Industry Association) in Europe.
Daniel Zakowski
CEO, Ready Set Food
Daniel Zakowski is the CEO and co-founder of Ready, Set, Food! After senior roles in corporate strategy and operations at companies like The Wonderful Company and AECOM, Daniel founded Ready, Set, Food! after his nephew developed severe food allergies in 2017. Through their unique patented products and education, their goal is to help make it easy for all parents to implement the food allergy prevention guidelines and to effectively end the burgeoning food allergy epidemic. In addition to selling products at important US retailers like Walmart, Target, Walgreens, and Kroger, they are very excited to have formed educational partnerships with large health systems like Providence Health, Northwell, and others.
Don't miss out.
Register by 16th June 2023 . We look forward to seeing you there.
Please contact our event manager, Matthew Brookes
[email protected]
[email protected]
Conference Location
The Royal Society of Medicine
1 Wimpole St, London W1G 0AE. UK
The Royal Society of Medicine is a historical, high-quality venue located in the heart of London’s West End. It has a long and rich history as a cross-specialty society sharing medical and healthcare knowledge. It contains Europe’s largest medical library and has hosted prominent figures in medicine and science such as Charles Darwin, Sigmund Freud, and Sir Alexander Fleming.
1 Wimpole St, London W1G 0AE. UK
The Royal Society of Medicine is a historical, high-quality venue located in the heart of London’s West End. It has a long and rich history as a cross-specialty society sharing medical and healthcare knowledge. It contains Europe’s largest medical library and has hosted prominent figures in medicine and science such as Charles Darwin, Sigmund Freud, and Sir Alexander Fleming.
Nearest Hotels
Radisson Bond Street
350 Oxford St, London W1C 1BY
020 7629 7474
The Mandeville Hotel
Mandeville Place London W1U 2BE
020 7935 5599
350 Oxford St, London W1C 1BY
020 7629 7474
The Mandeville Hotel
Mandeville Place London W1U 2BE
020 7935 5599
Holiday Inn London
Oxford Circus
57-59 Welbeck St
London W1G 9BL
020 7935 4442
3 min taxi / 3 min walk
Oxford Circus
57-59 Welbeck St
London W1G 9BL
020 7935 4442
3 min taxi / 3 min walk
London Marriott Hotel
Marble Arch
134 George St
London W1H 5DN
5 min taxi / 20 min walk
Marble Arch
134 George St
London W1H 5DN
5 min taxi / 20 min walk
Hilton London Metropole
225 Edgware Rd
London W2 1JU
02074024141
10 min taxi / 25 min walk
225 Edgware Rd
London W2 1JU
02074024141
10 min taxi / 25 min walk
Sponsors
Thank you to all our amazing sponsors without whose support the inaugural “The World Without Disease Summit” would not be possible
Interested in sponsoring? Please contact Matthew Brookes
To arrange a meeting to discuss this event please reach out to us as soon as possible as we anticipate the limited number of sponsorship opportunities will be sold quickly.
Organising Committee Co-Chairs
• Ben Wiegand: Founder, CWWDA
• Paul Tunnah: Founder, pharmaphorum
Sponsorship Sales & Event Manager
• Matthew Brookes
[email protected].
Organising Committee Co-Chairs
• Ben Wiegand: Founder, CWWDA
• Paul Tunnah: Founder, pharmaphorum
Sponsorship Sales & Event Manager
• Matthew Brookes
[email protected].
© 2023. All Rights Reserved.
pharmaphorum media limited, Rosemount House, Rosemount Avenue, West Byfleet, KT14 6LB, UK
Registered in England & Wales with no. 07254094, VAT registration no. 104 3777 29
pharmaphorum media limited, Rosemount House, Rosemount Avenue, West Byfleet, KT14 6LB, UK
Registered in England & Wales with no. 07254094, VAT registration no. 104 3777 29